Biolexis Raises $10M in Series A Funding to Advance AI-Driven Drug Discovery for Multiple Diseases
Biolexis Therapeutics focuses on developing small molecules targeting a range of diseases including cancers, immune-mediated, neurodegenerative, autoimmune, metabolic, and inflammatory conditions
Company Name: Biolexis Therapeutics
Location: American Fork, UT, USA
Sector: AI-Driven Drug Discovery in Biopharmaceuticals
Funding Details: Raised $10M in Series A funding
- Funding led by: Clarke Capital
- Purpose of Investment: Expand operations and accelerate clinical development of key drug candidates
Leadership: David Bearss, CEO
Product: MolecuLern™ AI-enabled drug discovery process
About: A clinical-stage biopharmaceutical company, Biolexis Therapeutics focuses on developing small molecules targeting a range of diseases including cancers, immune-mediated, neurodegenerative, autoimmune, metabolic, and inflammatory conditions. Their proprietary MolecuLern™ process uses AI to significantly speed up drug discovery, targeting any class of protein to identify novel chemical entities (NCEs) with drug-like characteristics. The process also involves real wet-lab data validation, reducing the typical timeline of discovery and development from years to months.
- Current Progress: Biolexis has 40 active programs in discovery and 10 pipeline programs in the IND-enabling stages of development.